Specialty Pharma Journal Specialty, Precision & Technology
SAN DIEGO, Calif.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today highlighted data from the ECHELON-1 phase 3 clinical trial evaluating ADCETRIS (brentuximab vedotin) in combination with AVD (Adriamycin®, vinblastine and dacarbazine) in newly diagnosed stage III or IV classical Hodgkin lymphoma (HL) at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition …
Tag Archives: Adcetris
December, 2018
November, 2018
-
19 November
FDA Approves Adcetris Plus Chemo for Adults with Previously Untreated Systemic Anaplastic Large Cell Lymphoma or Other CD30-Expressing Peripheral T-Cell Lymphomas
BOTHELL, Wash.–(BUSINESS WIRE)–Nov. 16, 2018– Seattle Genetics, Inc. (Nasdaq:SGEN) today announced a new approval for ADCETRIS® (brentuximab vedotin) in combination with CHP chemotherapy (cyclophosphamide, doxorubicin, prednisone) from the U.S. Food and Drug Administration (FDA) for adults with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell …
-
15 November
FDA Grants Breakthrough Therapy Designation to Seattle Genetics’ Adcetris for Frontline Peripheral T-Cell Lymphomas
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ADCETRIS (brentuximab vedotin) for previously untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination …
-
5 November
Seattle Genetics Submits sBLA for Adcetris in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 ECHELON-2 trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with CD30-expressing …
October, 2018
-
3 October
Seattle Genetics and Takeda Announce Positive Phase 3 Results for Adcetris in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
BOTHELL, Wash. & CAMBRIDGE, Mass. & OSAKA, Japan–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502) announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint. The trial demonstrated a statistically significant improvement in progression-free survival (PFS) of ADCETRIS (brentuximab vedotin) in combination with CHP (cyclophosphamide, …
January, 2018
-
2 January
FDA Grants Priority Review to Seattle Genetics’ Adcetris in Frontline Advanced Hodgkin Lymphoma
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing a supplemental Biologics License Application (BLA) for ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. The FDA granted Priority Review for …
December, 2017
-
13 December
Seattle Genetics and Bristol-Myers Squibb Highlight Interim Results from Phase 1/2 Study in Hodgkin Lymphoma
ATLANTA–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN) and Bristol-Myers Squibb Company (NYSE:BMY) today highlighted updated interim results from an ongoing phase 1/2 clinical trial evaluating the combination of ADCETRIS (brentuximab vedotin) and Opdivo (nivolumab) in relapsed or refractory classical Hodgkin lymphoma (HL) at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition taking place in Atlanta, …
November, 2017
-
9 November
FDA Approves Seattle Genetics’ Adcetris for pcALCL and CD30-Expressing MF
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that the U.S. Food and Drug Administration (FDA) has approved ADCETRIS (brentuximab vedotin) for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy. Primary cutaneous ALCL and …
-
3 November
Seattle Genetics Submits sBLA to FDA for Adcetris in Frontline Advanced Hodgkin Lymphoma
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) based on data from the phase 3 ECHELON-1 trial evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced …
October, 2017
-
3 October
FDA Grants Breakthrough Therapy Designation to Seattle Genetics’ Adcetris in Frontline Advanced Hodgkin Lymphoma
BOTHELL, Wash.–(BUSINESS WIRE)–Oct. 2, 2017– Seattle Genetics, Inc. (NASDAQ:SGEN) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to ADCETRIS (brentuximab vedotin) in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma. The positive topline results of the phase 3 ECHELON-1 clinical trial …